BET inhibitors have shown promising in vitro and in vivo anticancer effects against MB, NUT-midline carcinoma, multiple myeloma, lymphoma, leukemia, and neuroblastoma [16, 23–25]. Here, DNER is linked to plasma cell myeloma.